ResMed Earnings Reflect Increased Demand For Sleep Devices, Performance Indicates Positive Dynamics, Opportunities
Portfolio Pulse from Vandana Singh
ResMed Inc. (NYSE:RMD) reported strong Q4 2024 earnings with revenue of $1.22 billion, driven by increased demand for sleep devices and masks. Gross margin improved significantly, and adjusted EPS beat consensus. The company also increased its quarterly dividend by 10%. Despite short-term challenges, analysts remain positive on ResMed's fundamentals. Eli Lilly (NYSE:LLY) released results from phase 3 trials for tirzepatide injection for obstructive sleep apnea.
August 02, 2024 | 2:46 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Eli Lilly released detailed results from phase 3 trials for tirzepatide injection for obstructive sleep apnea. This development could impact the market for sleep apnea treatments.
While the phase 3 trial results are significant, the immediate impact on Eli Lilly's stock price is uncertain. The news is more relevant for the long-term market for sleep apnea treatments.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
ResMed reported strong Q4 2024 earnings with revenue of $1.22 billion, driven by increased demand for sleep devices and masks. Gross margin improved, and adjusted EPS beat consensus. The company increased its quarterly dividend by 10%. Analysts remain positive on ResMed's fundamentals despite short-term challenges.
ResMed's strong earnings report, improved margins, and increased dividend are positive indicators for the stock. Analysts' positive outlook further supports a likely short-term price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100